Ischemic Stroke Clinical Trial
Official title:
Cardio-embolic Stroke and Blood Bio-markers:Diagnosis and Predictors of Short Term Outcome.
Brain is a productive source of variety of enzymes and any brain injury like stroke to brain tissue could similarly result in an increase in these enzymes in cerebrospinal fluid and serum. Evaluation of these enzymes represent a simple method for the ischemic stroke subtype diagnosis and prognosis .Objective: The aim of this study was to determine the role Brain natriuretic peptide (BNP) , D-Dimer , creatine kinase- MB(CK-MB) , C reactive protein (CRP) serum levels and G/A ratio in diagnosis of CES stroke and its ability to predict short term outcome. Methods: This study was conducted on 96 patients with acute ischemic stroke, subdivided into two groups, group Ι was 48 patients with cardio-embolic stroke and group ΙΙ was 48 patients with non- cardio-embolic. all patients were subjected to assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio within the first 24 h of stroke .At third week ,they were assessed by mRS.
participants and methods : 96 acute ischemic stroke patients divided to two groups ; group Ι
: 48 patients with cardio-embolic stroke (CES) and group ΙΙ: 48 patients with cerebrovascular
stroke other than cardio-embolic stroke (non CES), with first-ever acute ischemic stroke
within 24 h of onset of symptoms admitted to Intensive Care and Stroke Unit .
All patients were subjected to full detailed neurological history with stressing on the
vascular and cardiac risk factors , and general and neurological examination. Stroke severity
was assessed using Glasgow Coma Scale (GCS) and the National Institutes of Health Stroke
Scale (NIHSS)
Laboratory investigations:15 ml venous blood were obtained from the patients within the first
24 hours of stroke. All routine and special laboratory investigations were done at Clinical
pathology department, Zagazig university hospitals including CBC, liver function, kidney
function, ESR and lipid profile.
Brain natriuretic peptide : 4 ml blood was placed in a polypro pane tube containing a mixture
of sodium salt of ethylene diamine tetra acetic acid (EDTA) at a concentration of 1mg /ml of
blood and aprotinin at a concentration of 500 kallikerin inhibitory unit (kiu) /ml of blood
serving as a natural proteinase inhibitor which act as a preservative for natriuretic
peptides , then mixing of the blood was done . then the tube was centrifuged at 5000 rpm for
15 minutes in the cool centrifuge , the separated serum was stored at -70 degree c until
analysis.
Later on the assay was done using human BNP Elisa kits (Spain react kits sr 19369u) which are
immune-sorbent assay for quantitative measurement , the least sensitivity is 14 pg/ml and
ranges 14 -1000pg/ml .
D-Dimer: 3ml blood was collected within a vacuum tubes containing 0.5 ml buffered sodium
citrate before the initiation of any oral, enteral or parenteral feeding or medications.
Blood samples were mixed well with avoiding of foam formation then immediately centrifuged at
3000 rpm for 15 min at ambient room temperature and plasma is separated. D-Dimer was measured
turbidmetry (SAT Liatest D-Di; Diagnostica STAGO) on the STAgo compact analyzer, Normal value
is less than 500 ng / ml (15).
Creatine Kinase MB : 4 ml blood were derived within a plastic tube centrifuged at 4000rpm for
3minutes , the separated serum was assayed for CK MB using Spain react kits with normal value
up to 2.8ng /L C reactive protein : 4ml were withdrawn in a plastic tube centrifuged at
4000rpm for 3minutes , the separated serum used for analysis of CRP measured using Olympus
640 analyzer with normal value up to 5 mg / L Globulin/Albumin ratio( G/A) was calculated
with normal ratio 0.6-0.7 . All patients were evaluated by Brain CT or MRI for diagnosis of
ischemic stroke .
Each patient underwent to Electrocardiogram, Echocardiography and Carotid Doppler
ultrasonography to define etiological stoke subtype.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
| Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
| Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
| Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
| Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
| Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
| Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
| Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
| Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
| Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
| Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
| Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
| Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
| Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
| Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
| Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
| Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
| Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
| Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A |